IL155999A0 - Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists - Google Patents

Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists

Info

Publication number
IL155999A0
IL155999A0 IL15599901A IL15599901A IL155999A0 IL 155999 A0 IL155999 A0 IL 155999A0 IL 15599901 A IL15599901 A IL 15599901A IL 15599901 A IL15599901 A IL 15599901A IL 155999 A0 IL155999 A0 IL 155999A0
Authority
IL
Israel
Prior art keywords
phenylethinyl
phenylethenyl
derivatives
receptor antagonists
glutamate receptor
Prior art date
Application number
IL15599901A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL155999A0 publication Critical patent/IL155999A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15599901A 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists IL155999A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126615 2000-12-04
PCT/EP2001/013714 WO2002046166A1 (en) 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
IL155999A0 true IL155999A0 (en) 2003-12-23

Family

ID=8170567

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15599901A IL155999A0 (en) 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
IL155999A IL155999A (en) 2000-12-04 2003-05-19 PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF mGluR5 RECEPTOR MEDIATED DISORDERS

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155999A IL155999A (en) 2000-12-04 2003-05-19 PHENYLETHENYL OR PHENYLETHINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF mGluR5 RECEPTOR MEDIATED DISORDERS

Country Status (31)

Country Link
US (4) US6706707B2 (cs)
EP (1) EP1349839B8 (cs)
JP (2) JP4077317B2 (cs)
KR (1) KR100515549B1 (cs)
CN (1) CN1257894C (cs)
AR (1) AR035401A1 (cs)
AT (1) ATE288898T1 (cs)
AU (2) AU2956702A (cs)
BG (1) BG107877A (cs)
BR (1) BR0115871A (cs)
CA (1) CA2430696C (cs)
CZ (1) CZ20031795A3 (cs)
DE (1) DE60108900T2 (cs)
DK (1) DK1349839T3 (cs)
EC (1) ECSP034640A (cs)
ES (1) ES2248410T3 (cs)
HR (1) HRP20030429A2 (cs)
HU (1) HUP0400570A3 (cs)
IL (2) IL155999A0 (cs)
MA (1) MA26971A1 (cs)
MX (1) MXPA03004862A (cs)
NO (1) NO324326B1 (cs)
NZ (1) NZ525917A (cs)
PL (1) PL366222A1 (cs)
PT (1) PT1349839E (cs)
RS (1) RS43903A (cs)
RU (1) RU2284323C9 (cs)
SI (1) SI1349839T1 (cs)
SK (1) SK8402003A3 (cs)
WO (1) WO2002046166A1 (cs)
ZA (1) ZA200303870B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7074809B2 (en) 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
CA2495120A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
AU2004218180B2 (en) 2003-03-04 2009-11-12 Addex Pharma Sa Novel aminopyridine derivatives as mGluR5 antagonists
RU2333200C2 (ru) 2003-03-07 2008-09-10 Астеллас Фарма Инк. Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
US7507836B2 (en) 2003-03-26 2009-03-24 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
WO2005118568A1 (en) * 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
MXPA05013233A (es) * 2003-06-12 2006-03-09 Hoffmann La Roche Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
WO2005094822A1 (en) 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
TWI335816B (en) * 2004-05-26 2011-01-11 Eisai R&D Man Co Ltd Cinnamide compound
HRP20080363T3 (hr) 2004-06-01 2008-09-30 F. Hoffmann - La Roche Ag Piridin-4-il-etinil-imidazoli i pirazoli kao antagonisti mglu5 receptora
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
KR20070106690A (ko) * 2004-12-27 2007-11-05 아스트라제네카 아베 피라졸론 화합물 및 대사성 글루타메이트 수용체길항제로서 그들의 용도
KR20070112276A (ko) * 2005-03-16 2007-11-22 아벤티스 파마슈티칼스 인크. 중추신경계 약제로서의 디피라졸
PL1863818T3 (pl) * 2005-03-23 2010-08-31 Hoffmann La Roche Pochodne acetylenylo-pirazolo-pirymidyny jako antagoniści MGLUR2
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
JPWO2007058305A1 (ja) * 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体の製造方法
BRPI0618814A2 (pt) * 2005-11-24 2014-04-29 Eisai R&D Man Co Ltd Composto ou um sal farmacologicamente aceitável do mesmo, e, agente farmacêutico
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
US20070142477A1 (en) * 2005-12-19 2007-06-21 The University Of Liverpool Analgesia
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
PL1992618T3 (pl) * 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
SA07280403B1 (ar) * 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
CN101568531B (zh) 2006-12-21 2013-11-13 弗·哈夫曼-拉罗切有限公司 Mglur5受体拮抗剂的多晶型物
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
EP2181992B8 (en) * 2007-08-31 2013-06-26 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
BRPI0906688A2 (pt) * 2008-01-28 2015-06-30 Eisai R&D Man Co Ltd Sal, e, cristal
US8323805B2 (en) 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
JPWO2012015024A1 (ja) * 2010-07-29 2013-09-12 大正製薬株式会社 エチニル−ピラゾール誘導体
CA2814930C (en) * 2010-11-05 2019-02-12 Otsuka Agritechno Co., Ltd. Ethynylphenylamidine compound or salt thereof, method for producing same, and fungicide for agricultural and horticultural use
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
KR101291037B1 (ko) * 2011-10-12 2013-08-01 사회복지법인 삼성생명공익재단 레스베라트롤 유도체와 스티릴-오각형 방향족 화합물 및 이들의 베타-아밀로이드 플라그에 대한 결합제 및 진단영상제의 용도
WO2017117708A1 (en) * 2016-01-05 2017-07-13 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
US10669255B2 (en) 2016-04-06 2020-06-02 Hua Medicine (Shanghai) Ltd. Pyrrole derivatives
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
EP3661500A1 (en) 2017-07-31 2020-06-10 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
EP4069685A1 (en) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) * 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
RU2099330C1 (ru) 1989-06-30 1997-12-20 Е.И.Дюпон Де Немур Энд Компани Замещенные имидазолы или их фармацевтически приемлемые соли и фармацевтическая композиция
US5821937A (en) * 1996-02-23 1998-10-13 Netsuite Development, L.P. Computer method for updating a network design
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
BR9811933A (pt) * 1997-08-14 2000-09-05 Hoffmann La Roche Vinil éteres heterocìclicos contra distúrbios neurológicos
US6377987B1 (en) * 1999-04-30 2002-04-23 Cisco Technology, Inc. Mechanism for determining actual physical topology of network based on gathered configuration information representing true neighboring devices
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法

Also Published As

Publication number Publication date
US20050131043A1 (en) 2005-06-16
DE60108900T2 (de) 2006-01-12
DE60108900D1 (en) 2005-03-17
ZA200303870B (en) 2004-08-19
SK8402003A3 (en) 2004-04-06
RU2284323C2 (ru) 2006-09-27
JP2008169206A (ja) 2008-07-24
BR0115871A (pt) 2003-10-28
MA26971A1 (fr) 2004-12-20
HRP20030429A2 (en) 2005-04-30
BG107877A (bg) 2004-02-27
RS43903A (sr) 2006-12-15
MXPA03004862A (es) 2005-02-14
US20030225070A1 (en) 2003-12-04
CA2430696C (en) 2009-01-27
WO2002046166A1 (en) 2002-06-13
ECSP034640A (es) 2003-07-25
EP1349839A1 (en) 2003-10-08
NO20032503L (no) 2003-06-03
JP4077317B2 (ja) 2008-04-16
EP1349839B8 (en) 2005-06-22
US6927232B2 (en) 2005-08-09
KR20040025878A (ko) 2004-03-26
EP1349839B1 (en) 2005-02-09
CA2430696A1 (en) 2002-06-13
NZ525917A (en) 2005-11-25
AU2956702A (en) 2002-06-18
AU2002229567B2 (en) 2007-09-06
AR035401A1 (es) 2004-05-26
DK1349839T3 (da) 2005-06-06
NO324326B1 (no) 2007-09-24
HK1063318A1 (en) 2004-12-24
CZ20031795A3 (cs) 2004-01-14
HUP0400570A2 (hu) 2004-06-28
US20020128263A1 (en) 2002-09-12
RU2284323C9 (ru) 2007-01-20
CN1478080A (zh) 2004-02-25
JP2004520292A (ja) 2004-07-08
CN1257894C (zh) 2006-05-31
US6706707B2 (en) 2004-03-16
PT1349839E (pt) 2005-05-31
ES2248410T3 (es) 2006-03-16
IL155999A (en) 2009-09-01
KR100515549B1 (ko) 2005-09-20
HUP0400570A3 (en) 2004-09-28
US20030208082A1 (en) 2003-11-06
SI1349839T1 (cs) 2005-08-31
PL366222A1 (en) 2005-01-24
NO20032503D0 (no) 2003-06-03
ATE288898T1 (de) 2005-02-15
US6972299B2 (en) 2005-12-06

Similar Documents

Publication Publication Date Title
IL155999A0 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
IL154079A0 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
IL162377A0 (en) 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
AU9384701A (en) Metabotropic glutamate receptor antagonists
IL154053A0 (en) AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS alpha4 INTEGRIN ANTAGONISTS
PL369120A1 (en) Urea derivatives as integrin alpha 4 antagonists
HRP20030031A2 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
MXPA03006991A (es) Derivados de piperidina como antagonistas de neurocinina 1.
IL148623A0 (en) Thienoisoxazolyl-and thienylpyrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
IL145166A0 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
IL150272A0 (en) Indole derivatives as mcp-1 receptor antagonists
EG24179A (en) Vitronectin receptor antagonists
PL375263A1 (en) 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
IL160093A0 (en) Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists
SI1200400T1 (en) Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists
SI1216239T1 (en) Piperazine derivatives as 5-ht1b antagonists
SI1383750T1 (sl) Derivati uree kot integrin alfa 4 antagonisti